Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era-Reference-Cited by-同舟云学术

Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era

Published:2015-02 Issue:2 Volume:106 Page:179-185
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Takamatsu Hiroyuki¹,Honda Sumihisa²,Miyamoto Toshihiro³,Yokoyama Kenji⁴,Hagiwara Shotaro⁵,Ito Toshiro⁶,Tomita Naoto⁷,Iida Shinsuke⁸,Iwasaki Toshihiro⁹,Sakamaki Hisashi¹⁰,Suzuki Ritsuro¹¹,Sunami Kazutaka¹²

Affiliation:

1. Cellular Transplantation Biology (Hematology/Respirology) Institute of Medical, Pharmaceutical and Health Sciences Kanazawa UniversityJapan

2. Department of Nursing Nagasaki University Graduate School of Biomedical Sciences NagasakiJapan

3. Medicine and Biosystemic Science, Graduate School of Medical Sciences Kyushu University Hospital FukuokaJapan

4. Division of Hematology Department of Medicine Keio University School of Medicine TokyoJapan

5. Division of Hematology, Internal Medicine National Center for Global Health and Medicine TokyoJapan

6. Division of Hematology Second Department of Internal Medicine Shinshu University School of Medicine MatsumotoJapan

7. Department of Internal Medicine and Clinical Immunology Yokohama City University Graduate School of Medicine YokohamaJapan

8. Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences NagoyaJapan

9. Division of Hematology and Oncology Toyohashi Municipal Hospital ToyohashiJapan

10. Division of Hematology Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital TokyoJapan

11. Department of Hematopoietic Stem Cell Transplantation Data Management/Biostatistics Nagoya University School of Medicine NagoyaJapan

12. Department of Hematology National Hospital Organization Okayama Medical Center Okayama Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.12594

Reference16 articles.

1. International Staging System for Multiple Myeloma

2. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH-DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

3. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics

4. Improved survival in multiple myeloma and the impact of novel therapies

5. Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation;Cancer Science;2024-05-16

2. The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation;2023-11-17

3. Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: upfront transplant with MEL200 remains the standard of care;Annals of Hematology;2023-10-25

4. Treatment of multiple myeloma based on autologous stem cell transplant: An overview of systematic reviews;Medicine;2023-10-06

5. Mechanical complications in ST-elevation myocardial infarction: The impact of pre-hospital delay;International Journal of Cardiology;2021-12